2021 法国建议:白塞病的管理

2021-02-24 国外风湿免疫科相关专家小组 Orphanet J Rare Dis . 2021 Feb 24;16(Suppl 1):352.

白塞病是一种系统性变异性血管炎症性疾病,可累及皮肤、面膜、关节、眼、动静脉、神经系统和胃肠道系统。本文主要针对白塞病的管理提出指导建议,包括白塞病的诊断过程和初步评估,白塞病的治疗。共形成了30个要点

中文标题:

2021 法国建议:白塞病的管理

英文标题:

French recommendations for the management of Behçet's disease

发布日期:

2021-02-24

简要介绍:

白塞病是一种系统性变异性血管炎症性疾病,可累及皮肤、面膜、关节、眼、动静脉、神经系统和胃肠道系统。本文主要针对白塞病的管理提出指导建议,包括白塞病的诊断过程和初步评估,白塞病的治疗。共形成了30个要点总结了相关建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 法国建议:白塞病的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=62dc21c0020e312e, title=2021 法国建议:白塞病的管理, enTitle=French recommendations for the management of Behçet's disease, guiderFrom=Orphanet J Rare Dis . 2021 Feb 24;16(Suppl 1):352., authorId=0, author=, summary=白塞病是一种系统性变异性血管炎症性疾病,可累及皮肤、面膜、关节、眼、动静脉、神经系统和胃肠道系统。本文主要针对白塞病的管理提出指导建议,包括白塞病的诊断过程和初步评估,白塞病的治疗。共形成了30个要点, cover=https://img.medsci.cn/2021325/1616685576638_2020535.jpg, journalId=0, articlesId=null, associationId=893, associationName=国外风湿免疫科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Wed Feb 24 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>白塞病是一种系统性变异性血管炎症性疾病,可累及皮肤、面膜、关节、眼、动静脉、神经系统和胃肠道系统。本文主要针对白塞病的管理提出指导建议,包括白塞病的诊断过程和初步评估,白塞病的治疗。共形成了30个要点总结了相关建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=12598, tagName=白塞病)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=12598, guiderKeyword=白塞病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10077, appHits=193, showAppHits=0, pcHits=1153, showPcHits=9884, likes=0, shares=12, comments=19, approvalStatus=1, publishedTime=Thu Mar 25 23:31:11 CST 2021, publishedTimeString=2021-02-24, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Thu Mar 25 23:19:42 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 15:50:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 法国建议:白塞病的管理.pdf)])
2021 法国建议:白塞病的管理.pdf
下载请点击:
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214619, encodeId=46c2121461914, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:17 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213171, encodeId=b28512131e171, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:13:38 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212661, encodeId=b48f121266167, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:44:33 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190822, encodeId=3a2f11908229e, content=收到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:13:31 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085350, encodeId=71da10853501c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Wed Dec 29 09:30:12 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1214619, encodeId=46c2121461914, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:17 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213171, encodeId=b28512131e171, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:13:38 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212661, encodeId=b48f121266167, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:44:33 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190822, encodeId=3a2f11908229e, content=收到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:13:31 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085350, encodeId=71da10853501c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Wed Dec 29 09:30:12 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-04-21 135434d0m28暂无昵称

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214619, encodeId=46c2121461914, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:17 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213171, encodeId=b28512131e171, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:13:38 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212661, encodeId=b48f121266167, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:44:33 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190822, encodeId=3a2f11908229e, content=收到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:13:31 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085350, encodeId=71da10853501c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Wed Dec 29 09:30:12 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-04-19 qqnded

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214619, encodeId=46c2121461914, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:17 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213171, encodeId=b28512131e171, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:13:38 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212661, encodeId=b48f121266167, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:44:33 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190822, encodeId=3a2f11908229e, content=收到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:13:31 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085350, encodeId=71da10853501c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Wed Dec 29 09:30:12 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-02-07 245462683

    收到

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1214619, encodeId=46c2121461914, content=<a href='/topic/show?id=d945e1670d9' target=_blank style='color:#2F92EE;'>#白塞病#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71670, encryptionId=d945e1670d9, topicName=白塞病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Apr 26 15:38:17 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213171, encodeId=b28512131e171, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:13:38 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212661, encodeId=b48f121266167, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:44:33 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190822, encodeId=3a2f11908229e, content=收到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Mon Feb 07 20:13:31 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085350, encodeId=71da10853501c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210824/0129edd25da34fd4ab94ad0a178c2a63/17d82f91f91640318b49f92cf918d543.jpg, createdBy=208d102754, createdName=含子, createdTime=Wed Dec 29 09:30:12 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 含子

    学习了

    0

拓展阅读

2011 白塞病诊断和治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2011-05-01

2018 EULAR建议:白塞氏综合征的管理(更新版)

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2018-04-06

2018 日本白塞病皮肤黏膜病变治疗指南

日本皮肤病协会(JDA,Japanese Dermatological Association) · 2020-01-06

中国白塞综合征中西医结合诊疗专家共识(2020年)

中国风湿免疫科相关专家小组(统称) · 2021-02-20

2014 ICBD 国际白塞病诊断标准

暂未更新 · 2013-02-26